ReviewJournal of microbiology and biotechnology2026
Current Single-cell Proteins as Ingredients: Functions, Challenges, and Regulatory Frameworks.
Review in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell proteins (SCPs) broadly comprise microbial biomass or biomass-derived proteinaceous products produced from bacteria, yeasts, filamentous fungi, or microalgae. In the broader field of cell-derived alternative proteins, animal- and plant-cell-derived platforms are also being explored because they can reproduce the structural, compositional, and sensory equality of conventional food materials. In contrast, microbial SCPs are distinguished by diverse cellular structures, metabolites, cell-wall components, and bioactive fractions that may confer functionality beyond nutritional supplementation. This review summarizes recent progress in SCP-related platforms by first contrasting animal- and plant-cell-derived proteins with microbial SCPs, and then focusing on bacterial, yeast, filamentous fungal, and algal SCPs. Recent animal, human, and cell-based studies indicate that microbial SCPs and related microbial biomasses may modulate the gut microbiota, intestinal barrier function, immune and oxidative-stress responses, lipid metabolism, muscle protein synthesis, disease resistance, and product-quality traits. Nevertheless, microbial SCP development remains constrained by microbial-group-specific safety and processing issues, including nucleic acid reduction, toxin and contaminant control, and cell-wall-associated digestibility. Finally, this review summarizes regulatory frameworks for SCPs in the United States and the European Union, where commercialization remains product-specific rather than governed by a harmonized SCP category. Overall, SCPs represent promising but heterogeneous food and feed platforms that require integrated evaluation of nutritional value, functionality, safety, processing, and regulatory compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.